1.The influence and safety of denosumab on bone mineral density of lumbar spine in women with low bone mass: a meta-analysis.
Journal of Southern Medical University 2013;33(6):913-917
OBJECTIVETo evaluate the influence and safety of denosumab on bone mineral density (BMD) of lumbar spine in women with low bone mass.
METHODSThe clinical literatures concerning denosumab for the treatment of osteopenia or osteoporosis in women were searched from Medline, Embase, Cochrane Central Register of Controlled Trials, Wanfang database, China National Knowledge Infrastructure database, Chinese Biomedical Database. Randomized controlled trials (RCT) were selected by the inclusive and exclusive criteria. The jadad scale was used in the quality assessment of included studies. Meta-analysis of valid data picked from included studies was performed by RevMan 5.0.24 software.
RESULTS5 RCT were included in this meta-analysis. The results of meta-analysis using the fixed effects model showed that, the increase level of lumbar BMD after 12 month was 5.45% (95% CI, 5.05%~5.84%) higher in denosumab group than in placebo control group (P<0.00001). The serious adverse event, serious infection event and pack pain occurred during the followed-up were analysed using fixed effects model. The results showed no significant difference between two groups.
CONCLUSIONCompared with placebo control group, denosumab can significant increase the BMD of lumbar spine, and the safety of two groups is similar.
Antibodies, Monoclonal, Humanized ; adverse effects ; pharmacology ; Bone Density ; drug effects ; Bone Density Conservation Agents ; adverse effects ; pharmacology ; Denosumab ; Female ; Humans ; Lumbar Vertebrae ; Randomized Controlled Trials as Topic
2.Spontaneous Acetabular Periprosthetic Fracture in a Patient Continuously Having Zoledronic Acid.
Saran TANTAVISUT ; Aree TANAVALEE ; Voranuch THANAKIT ; Srihatach NGARMUKOS ; Vajara WILAIRATANA ; Yongsak WANGROONGSUB
Clinics in Orthopedic Surgery 2014;6(3):358-360
Zoledronic acid has been used for prevention of osteolytic and osteoblastic bone metastasis. This case report illustrates an undesirable consequence from prolonged usage of zoledronic acid in bone metastasis prevention. Periprosthetic acetabular fracture in a patient treated with zoledronic acid for 7 years was reported. The clinical presentation, radiographic and pathological results were described. This is a rare complication after total hip arthroplasty which should not be ignored especially in patients who received long term bisphosphonate.
Acetabulum/*injuries/pathology/surgery
;
Aged
;
Arthroplasty, Replacement, Hip/*adverse effects
;
Bone Density Conservation Agents/*adverse effects/pharmacology
;
Bone Neoplasms/prevention & control/secondary
;
Bone Remodeling/drug effects
;
Breast Neoplasms/pathology
;
Diphosphonates/*adverse effects/pharmacology
;
Female
;
Fractures, Spontaneous/chemically induced/etiology
;
Hip Prosthesis
;
Humans
;
Imidazoles/*adverse effects/pharmacology
;
Osteoarthritis, Hip/*surgery
;
Periprosthetic Fractures/*chemically induced/etiology
;
Prosthesis Failure
;
Reoperation